May 14, 2012

An FDA advisory panel voted 13 to 1 on Friday to support approval of a new single-treatment regimen for HIV. The once-daily pill, known as the "Quad," combines four drugs — emtricitabine, tenofovir, elvitegravir, and cobicistat — and is for treatment-naive adults. The FDA is expected to make a final approval decision by August 27.